Chinese (SSE) Pharma Industry Analysis
UpdatedJan 31, 2023
DataAggregated Company Financials
Companies213
- 7D-0.09%
- 3M7.1%
- 1Y0.6%
- YTD5.6%
The Pharma industry has been flat over the last week, but Shandong Shanda Wit Science and Technology has lost 8.7%. In line with that, the industry has also been flat over the past 12 months. Earnings are forecast to grow by 24% annually.
Industry Valuation and Performance
Has the Chinese Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 31 Jan 2023 | CN¥2.9t | CN¥771.3b | CN¥83.2b | 35.4x | 35x | 3.8x |
| Thu, 29 Dec 2022 | CN¥2.7t | CN¥771.4b | CN¥82.1b | 33.7x | 32.5x | 3.5x |
| Sat, 26 Nov 2022 | CN¥2.8t | CN¥767.8b | CN¥81.9b | 36.7x | 33.9x | 3.6x |
| Mon, 24 Oct 2022 | CN¥2.6t | CN¥760.7b | CN¥82.9b | 33.8x | 31.9x | 3.5x |
| Wed, 21 Sep 2022 | CN¥2.4t | CN¥759.6b | CN¥79.4b | 30.5x | 30.5x | 3.2x |
| Fri, 19 Aug 2022 | CN¥2.6t | CN¥753.5b | CN¥81.0b | 31.2x | 32.4x | 3.5x |
| Sun, 17 Jul 2022 | CN¥2.7t | CN¥744.9b | CN¥81.0b | 31x | 33.5x | 3.6x |
| Tue, 14 Jun 2022 | CN¥2.6t | CN¥740.2b | CN¥82.0b | 31.3x | 32x | 3.5x |
| Thu, 12 May 2022 | CN¥2.6t | CN¥740.3b | CN¥81.7b | 32.3x | 32x | 3.5x |
| Sat, 09 Apr 2022 | CN¥2.8t | CN¥724.6b | CN¥76.0b | 34x | 36.4x | 3.8x |
| Mon, 07 Mar 2022 | CN¥2.9t | CN¥726.3b | CN¥77.4b | 33.7x | 37.5x | 4x |
| Wed, 02 Feb 2022 | CN¥2.7t | CN¥721.5b | CN¥73.6b | 32.1x | 37.2x | 3.8x |
| Fri, 31 Dec 2021 | CN¥3.1t | CN¥718.2b | CN¥73.2b | 36.6x | 42.6x | 4.3x |
| Sun, 28 Nov 2021 | CN¥3.0t | CN¥717.1b | CN¥73.0b | 31.8x | 41.3x | 4.2x |
| Tue, 26 Oct 2021 | CN¥2.8t | CN¥704.5b | CN¥73.5b | 30.3x | 38.8x | 4x |
| Thu, 23 Sep 2021 | CN¥2.8t | CN¥702.7b | CN¥71.2b | 32.6x | 39.9x | 4x |
| Sat, 21 Aug 2021 | CN¥2.8t | CN¥702.6b | CN¥71.1b | 29.6x | 38.9x | 3.9x |
| Sat, 05 Jun 2021 | CN¥3.2t | CN¥680.8b | CN¥69.7b | 34x | 46.6x | 4.8x |
| Tue, 09 Mar 2021 | CN¥3.0t | CN¥646.4b | CN¥64.7b | 32.2x | 46.6x | 4.7x |
| Mon, 30 Nov 2020 | CN¥2.9t | CN¥635.4b | CN¥47.7b | 35.2x | 59.7x | 4.5x |
| Thu, 03 Sep 2020 | CN¥3.3t | CN¥626.5b | CN¥45.7b | 43.1x | 71.8x | 5.2x |
| Sun, 07 Jun 2020 | CN¥2.5t | CN¥629.7b | CN¥43.4b | 39.2x | 58.1x | 4x |
| Sat, 29 Feb 2020 | CN¥2.3t | CN¥644.0b | CN¥46.9b | 34.3x | 48.7x | 3.6x |
Price to Earnings Ratio
49.5x
Current Industry PE
- Investors are pessimistic on the Chinese Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 35.2x which is lower than its 3-year average PE of 45.2x.
- The industry is trading close to its 3-year average PS ratio of 4.1x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have grown 21% per year over the last three years.
- Revenues for these companies have grown 6.2% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | 0.71% | |
| Healthcare | -0.55% | |
| Pharma | -0.087% | |
| Pharma | -0.087% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 688506 Sichuan Biokin PharmaceuticalLtd | CN¥65.50 | 23.9% +CN¥5.1b | n/a | PS33x | |
| 600518 Kangmei Pharmaceutical | CN¥2.17 | 3.3% +CN¥970.5m | -32.0% | PE3.7x | |
| 300723 ApicHope Pharmaceutical | CN¥41.91 | 8.3% +CN¥922.1m | 50.8% | PE42.3x | |
| 600216 Zhejiang Medicine | CN¥12.49 | 6.7% +CN¥747.5m | -17.6% | PE15.4x | |
| 300026 Tianjin Chase Sun PharmaceuticalLtd | CN¥6.24 | 3.8% +CN¥691.0m | 1.1% | PE36x |